Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Liabilities: 2015-2024

Historic Other Non-Current Liabilities for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $3.8 million.

  • Cartesian Therapeutics' Other Non-Current Liabilities fell 76.39% to $848,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $848,000, marking a year-over-year decrease of 76.39%. This contributed to the annual value of $3.8 million for FY2024, which is 40.01% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Other Non-Current Liabilities is $3.8 million, which was down 40.01% from $6.4 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' Other Non-Current Liabilities peaked at $28.7 million during FY2020, and registered a low of $3.8 million during FY2024.
  • In the last 3 years, Cartesian Therapeutics' Other Non-Current Liabilities had a median value of $6.4 million in 2023 and averaged $9.8 million.
  • Data for Cartesian Therapeutics' Other Non-Current Liabilities shows a maximum YoY plummeted of 66.59% (in 2023) over the last 5 years.
  • Over the past 5 years, Cartesian Therapeutics' Other Non-Current Liabilities (Yearly) stood at $28.7 million in 2020, then fell by 11.44% to $25.4 million in 2021, then fell by 24.71% to $19.1 million in 2022, then crashed by 66.59% to $6.4 million in 2023, then plummeted by 40.01% to $3.8 million in 2024.